Biotechnology

Windtree Therapeutics

Windtree Therapeutics released FY2025 Q3 earnings on November 19, 2025 (EST), actual revenue USD 0 (forecast USD 3.2 M), actual EPS USD -1.0848 (forecast USD -53.9999)

Windtree Therapeutics released FY2025 9 Months Earnings on November 19 (EST), with actual revenue of USD 0 and EPS of USD -8.7762

Windtree Therapeutics released FY2025 Semi-Annual earnings on August 19 (EST), actual revenue USD 0, actual EPS USD -6.6683

Windtree Therapeutics released FY2025 Q2 earnings on August 19 (EST), actual revenue USD 0 (forecast USD 3 M), actual EPS USD -3.0586 (forecast USD -98.9999)

Windtree Therapeutics Inc terminates SEISMIC-C clinical study

Windtree Therapeutics Announces No New Safety Signals in ISTAROXIME Phase 2 Interim Analysis

Windtree Therapeutics Secures $60 Million Financing for BNB Treasury Strategy

Windtree Therapeutics Inc. Issues Convertible Notes and Warrants

Windtree Therapeutics ISTAROXIME Receives US Patent

Windtree Therapeutics Completes Recruitment of 20 Patients in SEISMIC C Study

Windtree Therapeutics Partners with Overseas Manufacturer to Cut Contraceptive Gel Manufacturing Costs

Windtree Receives Deficiency Letter from NASDAQ

Windtree Therapeutics Plans to Acquire Titan Environmental Services for $35 Million

Windtree Therapeutics Inc Acquires Titan Environmental Services

Windtree Announces Mid-Term Results of Istaroxime Phase II Study to be Released

Windtree Therapeutics released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 2.2 M), actual EPS USD -4.6327 (forecast USD -179.9998)

Windtree Therapeutics Reports Q1 2025 Earnings

Windtree Therapeutics Showcases New Compound Data for Heart Failure Treatment

Windtree Therapeutics raises $2.5m through private placement of D-series convertible preferred stock

Windtree Therapeutics released FY2024 Q4 earnings on April 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0.3959 (forecast USD -39)

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap